title: Diagnostic evaluation of papillary lesions of the breast on core biopsy.
abstract: The management of asymptomatic intraductal papillary lesions of the breast diagnosed on core biopsy poses a challenge for patients and clinicians, as the distinction between common benign lesions and atypical or malignant varieties may be difficult without formal excision. The aim of this study was to determine whether a combination of histopathologic and biomarker features could be used to accurately identify benign papillary lesions on core biopsy. An inclusive group of 127 excised papillary lesions was characterized by detailed histopathologic review and immunohistochemical staining for the basal markers cytokeratin 5/6 (CK5/6) and P63 and the proliferation marker Ki67. Comparison of benign, atypical, and malignant lesions revealed that the combination of broad, sclerotic fibrovascular cores, and epithelial CK5/6 staining was most commonly seen in benign papillomas. Ki67 staining revealed striking intralesional heterogeneity, but there was no difference between the high scores of benign, atypical, or malignant lesions (P=0.173). In a non-overlapping set of 42 cases, a binary classifier specifying benign lesions on the basis of thick fibrovascular cores and epithelial CK5/6 staining on core biopsy gave an overall misclassification rate of 4/42 (10%) when compared with the final excision diagnosis. Misclassified cases included 2/27 lesions ultimately diagnosed as benign and 2/2 atypical papillomas. All malignant lesions (n=13) were correctly assigned. The combined assessment of fibrovascular core thickness and CK5/6 staining on core biopsy distinguished benign from malignant papillary lesions, but did not separate benign from atypical cases. This approach may form a useful addition to the clinicopathologic evaluation of papillary lesions of the breast.
authors.affiliation: Department of Tissue Pathology, Institute of Clinical Pathology and Medical Research, Sydney West Area Health Service, Westmead, NSW, Australia. nirmala.pathmanathan@swahs.health.nsw.gov.au
authors.forename: Nirmala
authors.initials: N
authors.lastname: Pathmanathan
authors.forename: Ann-Flore
authors.initials: AF
authors.lastname: Albertini
authors.forename: Pamela J
authors.initials: PJ
authors.lastname: Provan
authors.forename: Jane S
authors.initials: JS
authors.lastname: Milliken
authors.forename: Elizabeth L
authors.initials: EL
authors.lastname: Salisbury
authors.forename: A Michael
authors.initials: AM
authors.lastname: Bilous
authors.forename: Karen
authors.initials: K
authors.lastname: Byth
authors.forename: Rosemary L
authors.initials: RL
authors.lastname: Balleine
mesh_terms: D014408:Biomarkers, Tumor / Q000032:analysis; D001706:Biopsy; D001943:Breast Neoplasms / Q000378:metabolism / Q000473:pathology*; D018270:Carcinoma, Ductal, Breast / Q000378:metabolism / Q000473:pathology*; D002291:Carcinoma, Papillary / Q000378:metabolism / Q000473:pathology*; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D018300:Papilloma, Intraductal / Q000378:metabolism / Q000473:pathology*
chemical_list: D014408:Biomarkers, Tumor